Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Obtains CE Mark for PIK3CA Mutation Assay

NEW YORK – Qiagen said on Monday that it has obtained CE marking for its Therascreen PIK3CA RGQ PCR kit to aid in identifying breast cancer patients with a PIK3CA mutation.

As such, the test is now commercially available in Europe. The real-time qualitative PCR assay is performed on Qiagen's Rotor-Gene Q MDx instrument and uses the company's QIAamp in vitro diagnostic DNA sample prep kits for formalin-fixed paraffin-embedded tissue and plasma.

The assay detects 11 clinically actionably PIK3CA mutations, which are estimated to be present in about 40 percent of hormone receptor-positive, HER2-negative advanced breast cancer cases. Qiagen has a worldwide co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on detection of mutations in PIK3CA.

Qiagen codeveloped the test in collaboration with Novartis in the US as a companion diagnostic for alpelisib (Piqray). The assay received US Food and Drug Administration approval for this use in May.

"We are convinced that our Therascreen PIK3CA Kit … will provide a valuable testing option for those seeking new ways to combat advanced breast cancer," Jonathan Arnold, vice president and head of oncology and precision diagnostics at Qiagen, said in a statement.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.